Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H29ClN2O3S |
| Molecular Weight | 509.059 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(O)C1=CN(C(=N1)C(C)(C)C2=CC=CC=C2Cl)C3=CC=C(C=C3)C4=CC=CC(=C4)S(C)(=O)=O
InChI
InChIKey=JLPURTXCSILYLW-UHFFFAOYSA-N
InChI=1S/C28H29ClN2O3S/c1-27(2,23-11-6-7-12-24(23)29)26-30-25(28(3,4)32)18-31(26)21-15-13-19(14-16-21)20-9-8-10-22(17-20)35(5,33)34/h6-18,32H,1-5H3
| Molecular Formula | C28H29ClN2O3S |
| Molecular Weight | 509.059 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:12:11 GMT 2023
by
admin
on
Sat Dec 16 05:12:11 GMT 2023
|
| Record UNII |
FB7ZTJ8M8A
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
FB7ZTJ8M8A
Created by
admin on Sat Dec 16 05:12:11 GMT 2023 , Edited by admin on Sat Dec 16 05:12:11 GMT 2023
|
PRIMARY | |||
|
BMS-779788
Created by
admin on Sat Dec 16 05:12:11 GMT 2023 , Edited by admin on Sat Dec 16 05:12:11 GMT 2023
|
PRIMARY | MedKoo CAT NO: 522686; CAS NO: 918348-67-1; Description: BMS-779788, also known as XL-652, EXEL 04286652 and BMS-788, is potent partial LXR agonist with LXR.BETA. selectivity, which has an improved therapeutic window in the cynomolgus monkey compared with a full pan agonist. BMS-779788 induced LXR target genes in blood in vivo with an EC50 = 610 nM, a value similar to its in vitro blood gene induction potency. BMS-779788 was 29- and 12-fold less potent than the full agonist T0901317 in elevating plasma triglyceride and LDL cholesterol, respectively, with similar results for plasma cholesteryl ester transfer protein and apolipoprotein B. (last updated: 4/4/2016). | ||
|
59251511
Created by
admin on Sat Dec 16 05:12:11 GMT 2023 , Edited by admin on Sat Dec 16 05:12:11 GMT 2023
|
PRIMARY | |||
|
918348-67-1
Created by
admin on Sat Dec 16 05:12:11 GMT 2023 , Edited by admin on Sat Dec 16 05:12:11 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545418
Created by
admin on Sat Dec 16 05:12:11 GMT 2023 , Edited by admin on Sat Dec 16 05:12:11 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Bristol-Myers Squibb, Exelixis; Developer: Bristol-Myers Squibb; Class: Antihyperlipidaemic, Small molecule; Mechanism of Action: Liver X receptor agonist; Highest Development Phase: No development reported for Atherosclerosis; Most Recent Events: 03 Jan 2014 No development reported - Phase-I for Atherosclerosis in Australia (PO), 23 Mar 2012 Phase-I development is ongoing, 28 Feb 2009 Phase-I clinical trials in Atherosclerosis in Australia (PO)
|
||
|
ACTIVE MOIETY |
BMS-779788 induced LXR target genes in blood in vivo with an EC50 = 610 nM, a value similar to its in vitro blood gene induction potency. BMS-779788 was 29- and 12-fold less potent than the full agonist T0901317 in elevating plasma triglyceride and LDL cholesterol, respectively, with similar results for plasma cholesteryl ester transfer protein and apolipoprotein B. However, ABCA1 and ABCG1 mRNA inductions in blood, which are critical for RCT, were comparable. Increased liver triglyceride was observed after 7-day treatment with BMS-779788 at the highest dose tested and was nearly identical to the dose response for plasma triglyceride, consistent with the central role of liver LXR in these lipogenic effects.
|
